The China factor: US pharma group campaigns for increased competitiveness

In the race to lead the innovation narrative, the US healthcare industry needs to actively consider systemic changes to contend with the growing competition from China, say industry experts. At the glitzy event organised by the lobbying group PhRMA on 17 February in Washington DC, several administration leaders mingled with leading pharma and biotech executives to discuss the latest trends and challenges in the pharmaceutical sector. The chief topic on the agenda for all was China; with PhRMA and others ...